SK100893A3 - Polyoxypropylene-polyoxyethylene copolymers with improved biological activity - Google Patents

Polyoxypropylene-polyoxyethylene copolymers with improved biological activity Download PDF

Info

Publication number
SK100893A3
SK100893A3 SK1008-93A SK100893A SK100893A3 SK 100893 A3 SK100893 A3 SK 100893A3 SK 100893 A SK100893 A SK 100893A SK 100893 A3 SK100893 A3 SK 100893A3
Authority
SK
Slovakia
Prior art keywords
copolymer
polyoxypropylene
polyoxyethylene
molecular weight
daltons
Prior art date
Application number
SK1008-93A
Other languages
English (en)
Slovak (sk)
Inventor
R Martin Emanuele
Robert L Hunter
Paula H Culbreth
Activity Logical
Original Assignee
Cytrx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27100911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK100893(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytrx Corp filed Critical Cytrx Corp
Publication of SK100893A3 publication Critical patent/SK100893A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/04—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers only
    • C08G65/06—Cyclic ethers having no atoms other than carbon and hydrogen outside the ring
    • C08G65/08—Saturated oxiranes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2603—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen
    • C08G65/2606—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups
    • C08G65/2609—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups containing aliphatic hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2618—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing nitrogen
    • C08G65/2621—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing nitrogen containing amine groups
    • C08G65/2624—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing nitrogen containing amine groups containing aliphatic amine groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/30—Post-polymerisation treatment, e.g. recovery, purification, drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Detergent Compositions (AREA)
  • Radar Systems Or Details Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
SK1008-93A 1991-03-19 1992-03-18 Polyoxypropylene-polyoxyethylene copolymers with improved biological activity SK100893A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67328991A 1991-03-19 1991-03-19
US84787492A 1992-03-13 1992-03-13
PCT/US1992/002254 WO1992016484A1 (fr) 1991-03-19 1992-03-18 Copolymeres de polyoxypropylene/polyoxyethylene presentant une activite biologique amelioree

Publications (1)

Publication Number Publication Date
SK100893A3 true SK100893A3 (en) 1994-04-06

Family

ID=27100911

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1008-93A SK100893A3 (en) 1991-03-19 1992-03-18 Polyoxypropylene-polyoxyethylene copolymers with improved biological activity

Country Status (19)

Country Link
US (7) US5523492A (fr)
EP (1) EP0576612B1 (fr)
JP (1) JP2647556B2 (fr)
KR (1) KR100224539B1 (fr)
CN (1) CN1069741A (fr)
AT (1) ATE187154T1 (fr)
AU (1) AU662146B2 (fr)
CA (1) CA2106474C (fr)
CZ (1) CZ194693A3 (fr)
DE (1) DE69230372T2 (fr)
DK (1) DK0576612T3 (fr)
ES (1) ES2140408T3 (fr)
GR (1) GR3032726T3 (fr)
HU (1) HUT67762A (fr)
IE (1) IE920860A1 (fr)
IL (1) IL101305A (fr)
NO (1) NO307890B1 (fr)
SK (1) SK100893A3 (fr)
WO (1) WO1992016484A1 (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674911A (en) * 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
US7202225B1 (en) 1993-10-15 2007-04-10 Emanuele R Martin Therapeutic delivery compositions and methods of use thereof
HUT67762A (en) * 1991-03-19 1995-04-28 Cytrx Corp Polyoxypropylene/polyoxiethylene copolymers with improved biological activity and process for producing thereof
US6933286B2 (en) 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
USRE38558E1 (en) 1991-03-19 2004-07-20 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US6277410B1 (en) * 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
DE69428521T2 (de) * 1993-02-02 2002-05-23 Xoma Technology Ltd Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
AU8076494A (en) * 1993-10-15 1995-05-04 Cytrx Corporation Therapeutic delivery compositions and methods of use thereof
US5932544A (en) * 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
EP1181937A3 (fr) 1994-08-09 2004-02-04 Cytrx Corporation Vaccin contenant des acides nucléiquées et adjuvant de vaccin
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
WO1998013069A2 (fr) 1996-09-09 1998-04-02 Supratek Pharma, Inc. Complements pharmaceutiques copolymeriques fluores
US6942859B2 (en) 1998-03-13 2005-09-13 University Of Southern California Red blood cells covalently bound with polymers
US6312685B1 (en) 1998-03-13 2001-11-06 Timothy C. Fisher Red blood cells covalently bound with two different polyethylene glycol derivatives
AU1312800A (en) * 1998-10-09 2000-05-01 Cytrx Corporation Method and composition for treating ischemia and sickle cell anemia
CN1762990A (zh) * 1999-06-08 2006-04-26 拉卓拉药物公司 包含氨基氧基的化合价平台分子
AU2001268228A1 (en) 2000-06-08 2001-12-17 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
CA2411167A1 (fr) * 2000-06-23 2002-01-03 Merck & Co., Inc. Adjuvants de vaccins polynucleotidiques et formulations contenant des tensioactifs cationiques, procedes d'utilisation associes
US6761824B2 (en) * 2000-08-17 2004-07-13 Reeve Lorraine E Process for the fractionation of polymers
US20040266983A1 (en) * 2000-08-17 2004-12-30 Reeve Lorraine E Purified polyoxyalkylene block copolymers
WO2002061040A2 (fr) * 2000-10-20 2002-08-08 Valentis, Inc. Preparations de diffusion de genes et methodes de traitement de pathologies ischemiques
US20040009940A1 (en) * 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
US6492881B2 (en) * 2001-01-31 2002-12-10 Compaq Information Technologies Group, L.P. Single to differential logic level interface for computer systems
NZ543953A (en) * 2001-04-24 2007-04-27 Univ Chicago Method and compositions for treating mammalian nerve tissue injuries
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
EP1539122B1 (fr) * 2002-07-29 2014-01-29 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques de 2,6-diisopropylphenol aqueux
US6966990B2 (en) 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing
WO2004060059A2 (fr) * 2002-12-23 2004-07-22 Vical Incorporated Procede de lyophilisation de complexes d'acide nucleique/copolymere sequence/tensioactif cationique
WO2004060363A1 (fr) * 2002-12-23 2004-07-22 Vical Incorporated Procede permettant de produire des medicaments steriles a base de polynucleotides
US7083748B2 (en) * 2003-02-07 2006-08-01 Ferro Corporation Method and apparatus for continuous particle production using supercritical fluid
AU2004224439B2 (en) * 2003-03-24 2010-07-15 Genzyme Corporation Temporary embolization using inverse thermosensitive polymers
US20060008531A1 (en) * 2003-05-08 2006-01-12 Ferro Corporation Method for producing solid-lipid composite drug particles
CN1929850B (zh) * 2003-09-05 2010-05-12 艾维动物健康公司 精制的聚氧丙烯/聚氧乙烯共聚物及其制备方法
JP4898447B2 (ja) 2003-10-14 2012-03-14 プルーロームド インコーポレイテッド 結石破砕術の際の腎結石破片の閉じ込め
WO2005046438A2 (fr) 2003-11-06 2005-05-26 Pluromed, Inc. Pince interne pour procedures chirurgicales
JP4521547B2 (ja) * 2004-04-15 2010-08-11 株式会社サンメディカル技術研究所 血液ポンプの流量推定装置
WO2006060723A2 (fr) * 2004-12-03 2006-06-08 Vical Incorporated Procedes de production de copolymere sequence/particules amphiphiles
AU2006216420B2 (en) * 2005-02-25 2010-07-15 The Regents Of The University Of Michigan Compositions and methods for treating and preventing cardiomyopathy and heart disease
CA2602654A1 (fr) 2005-04-05 2006-10-12 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Procede permettant de proteger des sites fonctionnels ou des epitopes sur des proteines
AU2006242509B2 (en) 2005-05-02 2011-08-04 Genzyme Corporation Non-lithotripsic kidney-stone therapy
US8815557B2 (en) * 2005-07-08 2014-08-26 University Of Chicago Compositions and methods for refolding of denatured proteins
WO2008018892A2 (fr) * 2005-12-22 2008-02-14 Pluromed, Inc. Procédés et kits destinés à traiter des lacérations et des blessures par perforation utilisant des polymères thermosensitifs inverses
JP5537152B2 (ja) * 2006-08-01 2014-07-02 フリクサス ファーマシューティカルズ， インコーポレイテッド 慢性進行性心不全のための処置
EP2061547A2 (fr) 2006-09-11 2009-05-27 Pluromed, Inc. Ballonnets et jupes d'occlusion atraumatiques et leurs méthodes d'utilisation
WO2008073938A2 (fr) * 2006-12-11 2008-06-19 Pluromed, Inc. Hémostase d'organes perfusés
US20080208163A1 (en) * 2007-02-22 2008-08-28 Pluromed, Inc. Use of Reverse Thermosensitive Polymers to Control Biological Fluid Flow Following a Medical Procedure
JP2010523569A (ja) * 2007-04-05 2010-07-15 フリクサス ファーマシューティカルズ， インコーポレイテッド 心不全を治療するための組成物および方法
AU2008287419A1 (en) * 2007-08-10 2009-02-19 Synthrx, Inc. Polymer therapy for the treatment of chronic microvascular diseases
EP2612868B1 (fr) 2007-11-01 2018-08-15 Astellas Pharma Inc. Acides nucléiques et polypeptides immunosuppresseurs
JP5613567B2 (ja) 2007-11-29 2014-10-22 ジェンザイム・コーポレーション 精製逆感熱性ポリマーを使用する内視鏡的粘膜切除
ES2436781T3 (es) 2007-12-17 2014-01-07 The Regents Of The University Of Michigan Composiciones y procedimientos de tratamiento y prevención de deficiencias de músculo esquelético
EP2350274B1 (fr) 2008-10-21 2019-01-23 The General Hospital Corporation Transplantation de cellules
DE102008043343A1 (de) * 2008-10-31 2010-05-06 Evonik Goldschmidt Gmbh Silikonpolyetherblock-Copolymere mit definierter Polydispersität im Polyoxyalkylenteil und deren Verwendung als Stabilisatoren zur Herstellung von Polyurethanschäumen
WO2010072769A1 (fr) 2008-12-23 2010-07-01 Basf Se Procédé de production de copolymères à blocs polyéther
EP3508197A1 (fr) 2009-10-21 2019-07-10 Otonomy, Inc. Modulation de la température de gélification de formulations contenant des poloxamères
GB201008902D0 (en) * 2010-05-27 2010-07-14 Imp Innovations Ltd Membrane enhanced polymer sythesis
BR112013002859B1 (pt) 2010-08-06 2020-10-06 The General Hospital Corporation D/B/A Massachusetts General Hospital Método e aparelho para tratamento de células
BR112013011858A2 (pt) 2010-11-15 2017-03-21 Mast Therapeutics Inc métodos para reforçar oxigenação de tecido comprometido
EP2685991A1 (fr) 2011-03-18 2014-01-22 Baxter International Inc Solutions de dialyse péritonéale comprenant des polymères de glucose
FR2977495B1 (fr) * 2011-07-07 2014-03-07 Sanofi Sa Composition pharmaceutique et forme galenique solide a haute teneur en dronedarone et son procede de preparation
US9662345B2 (en) 2013-06-14 2017-05-30 Professional Compounding Centers Of America Antibiotic composition for inhalation and irrigation
US20160235781A1 (en) 2013-10-16 2016-08-18 Mast Therapeutics, Inc. Diuretic induced alterations of plasma volume
JP6202471B2 (ja) 2013-10-31 2017-09-27 日油株式会社 医用ポリオキシプロピレン重合体の製造方法および医用ポリオキシプロピレン／ポリオキシエチレンブロック共重合体の製造方法
WO2016007542A1 (fr) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Thérapie de l'insuffisance cardiaque faisant appel à un poloxamère
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
EP3166617B1 (fr) * 2014-07-07 2024-01-10 LifeRaft Biosciences, Inc. Composition de poloxamère exempte d'eléments à durée de circulation prolongée, méthodes de production et utilisations
WO2016007562A1 (fr) * 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Méthodes et compositions permettant d'améliorer une hémostase
US20180353875A1 (en) * 2015-12-22 2018-12-13 Basf Se A process for purification of polyether block copolymers
JP2020506276A (ja) * 2017-02-09 2020-02-27 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ポリエーテルブロックコポリマーの精製方法
US11891510B2 (en) 2017-12-21 2024-02-06 Sigma-Aldrich Co. Llc Poloxamer compositions and methods of making and using same
JP2020063244A (ja) 2018-10-15 2020-04-23 アヴェント インコーポレイテッド 神経アブレーションのための組成物、システム、キット及び方法

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2674619A (en) * 1953-10-19 1954-04-06 Wyandotte Chemicals Corp Polyoxyalkylene compounds
US2979528A (en) * 1953-10-19 1961-04-11 Wyandotte Chemicals Corp Nitrogen-containing polyoxyalkylene detergent compositions
US3022335A (en) * 1955-03-30 1962-02-20 Wyandotte Chemicals Corp Surface active polyoxyalkylene compounds having a plurality of heteric polyoxypropylene-polyoxyethylene chains
US2854378A (en) * 1955-12-08 1958-09-30 Bristol Lab Inc Tetracycline suppository
US3036118A (en) * 1957-09-11 1962-05-22 Wyandotte Chemicals Corp Mixtures of novel conjugated polyoxyethylene-polyoxypropylene compounds
US3089818A (en) * 1960-06-02 1963-05-14 Baxter Laboratories Inc Water dispersible antibiotics
US3228834A (en) * 1962-06-08 1966-01-11 Hoffmann La Roche Pharmaceutical diluent compositions
US3140232A (en) * 1962-12-19 1964-07-07 Pfizer & Co C Color stabilization of tetracycline compositions with polypropylene glycols
US3391196A (en) * 1965-08-16 1968-07-02 Wyandotte Chemicals Corp High equivalent weight hydroxy-terminated ethylene oxide-butylene oxide polyether polyols
US3740421A (en) * 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
US3450502A (en) * 1967-09-25 1969-06-17 Wyandotte Chemicals Corp Method of operating heart-lung apparatus
US3641240A (en) * 1968-09-27 1972-02-08 Wyandotte Chemicals Corp Method for the treatment of an embolus or thrombus
US3867533A (en) * 1968-12-20 1975-02-18 Basf Wyandotte Corp Preparation of aqueous gel compositions containing a water-insoluble organic ingredient
US3577522A (en) * 1969-10-10 1971-05-04 Wyandotte Chemicals Corp Methods for the treatment of shock with ethylene oxide-polypropylene glycol condensates as blood plasma substitutes
US3590125A (en) * 1969-10-10 1971-06-29 Wyandotte Chemicals Corp Physiological salt solutions of ethylene oxide-polypropylene glycol condensation products as blood plasma substitutes
US3980772A (en) * 1969-12-02 1976-09-14 Baxter Laboratories, Inc. Methods of dissolving blood clots and the like with streptokinase chemically bonded to a carbohydrate matrix
CA959759A (en) * 1970-01-15 1974-12-24 John J. Miskel Method for absorption of drugs
US3867521A (en) * 1970-08-26 1975-02-18 Scherer Corp R P Method for absorption of drugs
US4073886A (en) * 1973-01-30 1978-02-14 Baxter Travenol Laboratories, Inc. Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene
US3956259A (en) * 1973-01-30 1976-05-11 Baxter Laboratories, Inc. Fractionation of blood using block copolymer of ethylene oxide and polyoxypropylene polymer to recover fraction suitable for organ perfusate
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3997458A (en) * 1974-04-12 1976-12-14 Deknatel, Incorporated Method of cleansing contaminated wounds and surgical scrub solutions for same
US4104455A (en) * 1975-03-25 1978-08-01 Toyo Soda Manufacturing Co., Ltd. Polymerization of monomer
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4195167A (en) * 1976-05-28 1980-03-25 Union Carbide Corporation Gradient polymers of two or more cyclic, organic, ring-opening, addition polymerizable monomers and methods for making same
JPS545094A (en) 1977-06-09 1979-01-16 Tokyo Tanabe Co Production of pharmaceutical urokinase from contamination free human urine
DE2732929A1 (de) * 1977-07-21 1979-02-01 Bayer Ag Polyaether, verfahren zu ihrer herstellung sowie ihre verwendung als lipidabsorptionshemmer
EP0003399B1 (fr) * 1978-01-27 1981-11-25 BP Chemicals Limited Procédé pour augmenter la selectivité pour l'acide acétique dans la préparation d'un mélange d'acides monocarboxyliques contenant de 1 à 3 atomes de carbone par oxydation d'hydrocarbures de paraffine
DE2808865A1 (de) * 1978-03-02 1979-09-13 Hoechst Ag Mikrobiozide mittel auf der basis von alkyl-di-guanidinium-salzen
US4275244A (en) * 1978-05-11 1981-06-23 Basf Wyandotte Corporation Linear polyalkylene ether glycols of high molecular weight
JPS5533194A (en) 1978-08-07 1980-03-08 Scholz D Thomas Stringgfastener device including tremolant
US4305922A (en) * 1978-10-04 1981-12-15 University Patents, Inc. Labeling proteins with 99m-Tc by ligand exchange
US4186253A (en) * 1978-10-10 1980-01-29 The Green Cross Corporation Perfusate for preserving organ to be transplanted and preserving method
DE2850058A1 (de) * 1978-11-18 1980-05-29 Bayer Ag Polyaether-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2454409A1 (fr) * 1979-04-18 1980-11-14 Sovam Vehicule tracteur notamment pour avions gros porteurs
US4409209A (en) * 1979-10-12 1983-10-11 Ciba-Geigy Corporation Novel phosphorylmuramyl peptides and processes for the manufacture thereof
FI803077A (fi) * 1979-10-12 1981-04-13 Ciba Geigy Ag Foerfarande foer framstaellning av myramylpeptider
US4575484A (en) * 1980-05-05 1986-03-11 Montefiore Medical Center, Inc. Binding assay for the detection of mycobacteria
US4489158A (en) * 1980-05-05 1984-12-18 Montefiore Hospital And Medical Center, Inc. Binding assay for the detection of mycobacteria
US4410660A (en) * 1980-05-05 1983-10-18 Montefiore Medical Center Binding assay for the detection of mycobacteria
JPS578223A (en) * 1980-06-19 1982-01-16 Mitsui Petrochem Ind Ltd Production of alkylene oxide block copolymer
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction
US4376118A (en) * 1980-10-06 1983-03-08 Miles Laboratories, Inc. Stable nonaqueous solution of tetracycline salt
GR78246B (fr) * 1981-01-23 1984-09-26 Ciba Geigy Ag
US4395393A (en) * 1981-08-10 1983-07-26 Basf Wyandotte Corporation Artificial blood emulsifiers
US4407790A (en) * 1981-09-25 1983-10-04 Economics Laboratory, Inc. Method of controlling bloat using nonionic surfactants
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
DE3234084A1 (de) * 1982-09-14 1984-03-15 B. Braun Melsungen Ag, 3508 Melsungen Pharmazeutische zubereitungen zur behandlung von unerwuenschten verwachsungen sowie deren verwendung
SU1183112A1 (ru) * 1983-08-04 1985-10-07 Научно-Исследовательский Институт Экспериментальной И Клинической Терапии Министерства Здравоохранения Гсср Способ лечени острой ишемии миокарда
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4600652A (en) * 1985-04-01 1986-07-15 Warner-Lambert Company Permanently bonded antithrombogenic polyurethane surface
US5114708A (en) * 1985-06-18 1992-05-19 Emory University Method for stimulating growth in animals
US5183687A (en) * 1985-06-18 1993-02-02 Emory University Method of treating poultry for coccidiosis
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4837014A (en) * 1986-05-15 1989-06-06 Emory University An improved method of treating sickle cell anemia
US5039520A (en) * 1986-05-15 1991-08-13 Emory University Plasma extender
US5032394A (en) * 1986-05-15 1991-07-16 Emory University Method of treating burns
US5198211A (en) * 1986-05-15 1993-03-30 Emory University Method of treating myocardial damage
US5064643A (en) * 1986-05-15 1991-11-12 Emory University Method for treating sickle cell disease
US4897263A (en) * 1986-05-15 1990-01-30 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5041288A (en) * 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US5080894A (en) * 1986-05-15 1992-01-14 Emory University Method and composition for reducing tissue damage
US5047236A (en) * 1986-05-15 1991-09-10 Emory University Method of treating stroke
US4801452A (en) * 1986-05-15 1989-01-31 Hunter Robert L Fibrinolytic composition
WO1987006836A1 (fr) * 1986-05-15 1987-11-19 Emory University Composition fibrinolytique
US4873083A (en) * 1986-05-15 1989-10-10 Emory University Fibrinolytic composition
US5017370A (en) * 1986-05-15 1991-05-21 Emory University Improved method of performing angioplasty procedures
US5071649A (en) * 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
US4879109A (en) * 1986-05-15 1989-11-07 Emory University Method for treating burns
US5030448A (en) * 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US5028599A (en) * 1986-05-15 1991-07-02 Emory University Method of treating mycardial damage
US4997644A (en) * 1986-05-15 1991-03-05 Emory University Method of treating adult respiratory distress syndrome
US5078995A (en) * 1986-05-15 1992-01-07 Emory University Fibrionolytic composition
AU6334586A (en) * 1986-05-15 1987-12-01 Emory University Composition and method for treating a thrombus and embolus
US5250294A (en) * 1986-05-15 1993-10-05 Emory University Improved perfusion medium for transplantation of organs
US4937070A (en) * 1986-05-15 1990-06-26 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5089260A (en) * 1986-05-15 1992-02-18 Emory University Method of treating ischemic tissue
JP2527942B2 (ja) * 1986-09-18 1996-08-28 ティーディーケイ株式会社 磁気記録媒体
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US4764567A (en) * 1986-11-20 1988-08-16 Basf Corporation Process for the preparation of polyoxyalkylene block polyethers having enhanced properties
AU1396588A (en) * 1987-02-20 1988-09-14 Emory University Antiinfective compounds and method of use
US5811088A (en) 1987-02-20 1998-09-22 Emory University Antiinfective compounds and methods of use
JPH07109520B2 (ja) 1987-02-24 1995-11-22 株式会社リコー 電子写真用感光体
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
DE4014923A1 (de) * 1990-05-10 1991-11-14 Basf Ag Verfahren zur herstellung von urethan- oder urethan- und isocyanuratgruppen enthaltenden hartschaumstoffen nach dem polyisocyanat-polyadditionsverfahren und die hierfuer geeigneten polyoxyalkylen-polyole
HUT67762A (en) * 1991-03-19 1995-04-28 Cytrx Corp Polyoxypropylene/polyoxiethylene copolymers with improved biological activity and process for producing thereof
US5294365A (en) * 1991-12-12 1994-03-15 Basf Corporation Hydroxypolyethers as low-foam surfactants
US5371253A (en) * 1993-12-14 1994-12-06 Arco Chemical Technology, L.P. Process for producing esterified alkoxylated monoglycerides and diglycerides

Also Published As

Publication number Publication date
WO1992016484A1 (fr) 1992-10-01
US5990241A (en) 1999-11-23
DE69230372T2 (de) 2000-06-15
DK0576612T3 (da) 2000-05-22
NO933337D0 (no) 1993-09-17
EP0576612A1 (fr) 1994-01-05
US6747064B2 (en) 2004-06-08
HU9302628D0 (en) 1993-12-28
GR3032726T3 (en) 2000-06-30
US5523492A (en) 1996-06-04
KR100224539B1 (ko) 1999-10-15
HUT67762A (en) 1995-04-28
AU662146B2 (en) 1995-08-24
ATE187154T1 (de) 1999-12-15
EP0576612A4 (fr) 1994-11-09
US5691387A (en) 1997-11-25
EP0576612B1 (fr) 1999-12-01
CA2106474C (fr) 2004-02-10
USRE37285E1 (en) 2001-07-17
CN1069741A (zh) 1993-03-10
US20020183398A1 (en) 2002-12-05
US6359014B1 (en) 2002-03-19
IE920860A1 (en) 1992-09-23
IL101305A (en) 1995-11-27
JPH06506258A (ja) 1994-07-14
AU1773092A (en) 1992-10-21
USRE36665E (en) 2000-04-18
CZ194693A3 (en) 1994-03-16
ES2140408T3 (es) 2000-03-01
NO307890B1 (no) 2000-06-13
CA2106474A1 (fr) 1992-09-20
IL101305A0 (en) 1992-11-15
DE69230372D1 (de) 2000-01-05
JP2647556B2 (ja) 1997-08-27
NO933337L (no) 1993-11-17

Similar Documents

Publication Publication Date Title
SK100893A3 (en) Polyoxypropylene-polyoxyethylene copolymers with improved biological activity
US5696298A (en) Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
IE83219B1 (en) Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
EP0409940B1 (fr) Procedes et compositions servant au traitement des interactions hydrophobes pathologiques dans des fluides biologiques
US5567859A (en) Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US5674911A (en) Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
US20100209509A1 (en) Bifunctional-modified hydrogels
USRE38558E1 (en) Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US20220354801A1 (en) Multifunctional Nanoparticles For Prevention And Treatment Of Atherosclerosis
AU656224B2 (en) Method for treating vascular obstructions caused by abnormal cells
EP1415663A1 (fr) Preparations d'hydrogel hgf a liberation prolongee
WO2017007917A1 (fr) Copolymères de polyoxyéthylène/polyoxypropylène et inhibiteurs fibrinolytiques, leurs utilisations et compositions
WO2016007562A1 (fr) Méthodes et compositions permettant d'améliorer une hémostase
EP2923695A1 (fr) Sulfates de polyglycérol hyperramifié à c'urs hydrophobes
JP2005281665A (ja) 生体適合性を有する樹脂
US6054492A (en) Fluorinated copolymeric pharmaceutical adjuncts
REEVE 12. The poloxamers: their chemistry and medical applications
US7863408B2 (en) Body fluid compatible and biocompatible resin
EP2842548A1 (fr) Nouvel antidote synthetique
Singh Biocompatible and biodegradable nanogels and hydrogels for protein/peptide delivery
Wen The chemical modification of hyperbranched polyglycerols for improved bioadhesive and hemostatic properties
Crofton Chitosan decontamination with non-thermal nitrogen plasma to enable internal use
Moghimi Recent developments and limitations of poloxamine-coated long-circulating particles in experimental drug delivery
Alizadeh Noghani Progesterone-binding modified hyperbranched polyglycerols: synthesis, characterization and biological assessment
US20080226725A1 (en) New and Advantageous Hydrogel Composition